Original

Investigation

Publication Year

First Author

# of weeks to first follow-up encounter, at least 3 months (at 12 weeks) since onset of semaglutide dose

Starting dose semaglutide

Estimated Mean Percent Weight Loss (%) at first follow-up encounter

Estimated Mean Percent Weight Loss (%) at second follow-up encounter (if applicable)

Percent Weight Loss (%) at third follow-up encounter (if applicable)

p-value reported

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

2022

Garvey

12

2.4 mg

5.90%

12.20%

15.20%

p < 0.0001

Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity.

2022

Ghusn

12

1.7 mg

5.70%

10.90%

n/a

p < 0.001

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

The STEP 3 Randomized Clinical Trial

2021

Wadden

68

2.4 mg

16.00%

n/a

n/a

p < 0.001

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

2017

Ahren

56

1.0 mg

5.50%

n/a

n/a

p < 0.0001

Average # of weeks to attain average percent weight loss

37

8.28%

Average percent weight loss from the four original studies listed